Delcath Systems (NASDAQ:DCTH) Stock Rating Raised to “Strong-Buy” at Zacks Research

Delcath Systems (NASDAQ:DCTH) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

Several other brokerages have also commented on DCTH. BTIG Research boosted their price target on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. HC Wainwright increased their price objective on shares of Delcath Systems from $32.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $29.33.

Delcath Systems Trading Down 1.8%

Shares of DCTH opened at $21.38 on Wednesday. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $22.51. The stock’s 50 day moving average is $15.80 and its two-hundred day moving average is $12.65. The firm has a market cap of $743.81 million, a P/E ratio of 133.62 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. The business had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million. Equities research analysts forecast that Delcath Systems will post 0.13 EPS for the current year.

Institutional Trading of Delcath Systems

Several large investors have recently made changes to their positions in DCTH. Russell Investments Group Ltd. lifted its holdings in Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock valued at $1,417,000 after purchasing an additional 21,069 shares in the last quarter. Alps Advisors Inc. grew its holdings in shares of Delcath Systems by 30.3% during the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after buying an additional 10,600 shares in the last quarter. Kopp Family Office LLC purchased a new stake in shares of Delcath Systems during the third quarter worth $450,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Delcath Systems during the second quarter worth $48,000. Finally, IFP Advisors Inc acquired a new stake in shares of Delcath Systems in the second quarter valued at about $52,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems News Roundup

Investors following DCTH have been watching these news items:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 price target while lifting its FY2026 EPS estimate to $0.13 from a projected loss of $0.17 and its FY2027 estimate to $0.33 from $0.12. The higher forecasts imply improved expectations for profitability. Article: HC Wainwright earnings estimate revisions
• Positive Sentiment: A Zacks report says the analyst consensus price target suggests 27.7% upside and notes that upward earnings-estimate revisions could support the stock. It cautions, however, that price targets alone have limited predictive value. Article: Wall Street analysts see potential upside
• Neutral Sentiment: Delcath is scheduled to appear on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The feature may raise awareness, but the announcement gives no indication of a direct financial impact. Article: Delcath to be featured on Health Uncensored

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.